Senseonics, TypeZero Join Forces On Artificial Pancreas
Executive Summary
Diabetes companies Senseonics and TypeZero Technologies have signed a research and development licensing agreement to develop an artificial pancreas.
You may also be interested in...
ADA2018: Senseonics' Implantable CGM Beats Abbott, Dexcom In Head-To-Head Study – But Is Methodology Flawed?
In a three-way patient study comparing the accuracy of three currently available continuous glucose monitoring (CGM) devices, the newly FDA-approved Eversense by Senseonics performed significantly better than the Abbott Freestyle Libre Pro and Dexcom G5. The study findings were presented during this year's annual American Diabetes Association meeting in Orlando, Florida. This article also discusses other highlights presented by the three companies at the ADA conference.
Medtronic Stands To Be Biggest Beneficiary Of J&J's Exit From Insulin Pump Market
Animas, a division of Johnson & Johnson, will stop making Animas Vibe and OneTouch Ping insulin pumps, close operations, and exit the insulin pump business, the company announced Oct. 5. J&J is offering patients currently using these devices the option to transfer to Medtronic device. Medtronic is already the leading supplier of insulin pumps worldwide.
Market Intel: Advent Of Artificial Pancreas Tech To Galvanize Fast-Growing Diabetes Market
The global diabetes management devices market is expected to exceed $11.2bn by 2020, driven largely by the rising diabetes epidemic. This, in turn, is fueling significant innovation such as next-generation, automated artificial pancreas systems and miniaturized, less-invasive wireless technologies that can continuously track and analyze glucose levels in real-time. This feature looks more closely at these and other potentially groundbreaking new technologies, as well as the competitive landscape of the two major product segments – insulin pumps and blood glucose monitors.